Erik Scalfaro
CEO & Co-founder

Erik Scalfaro

Erik has spent the last decade solving drug development challenges with software. With +5 years experience in Pharma & Biotech, he was most recently at IQVIA developing analytics and launch strategies. Prior, he was at Novartis, and is a reserve Data Scientist in the Swiss Army.

‍

Interesting Fact:

Loves to ski tour and on track to summit all peaks of the Alps above 4K meters. Previously co-developed a resource planning software for hospitals that maximizes efficiency and limited delays of infusion suites treating multiple sclerosis patients.

Browse case studies

Articles by Erik Scalfaro

1. Lacinova, K., Thokala, P., Nicholas, R. et al. ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients. Appl Health Econ Health Policy20, 731–742 (2022). https://doi.org/10.1007/s40258-022-00733-0

2. Chowdary, P., Hampton, K., Jiménez-Yuste, V., Young, G., El Fegoun, S.B., Cooper, A., Scalfaro, E. and Tiede, A., 2022. Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response. Thrombosis and Haemostasis, 122(06), pp.913-925.

3. Helanterä, I., Snyder, J., Åsberg, A., Cruzado, J.M., Bell, S., Legendre, C., Tedesco-Silva Jr, H., Barcelos, G.T., Geissbühler, Y., Prieto, L. and Christian, J.B., 2022. Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence. Transplant International, 35, p.10329.

4. Scalfaro, E., Streefkerk, H.J., Merz, M., Meier, C. and Lewis, D., 2017. Preliminary results of a novel algorithmic method aiming to support initial causality assessment of routine pharmacovigilance case reports for medication-induced liver injury: the PV-RUCAM. Drug Safety, 40, pp.715-727.

Integrate clinical trial data in days. Generate insights forever.

Contact Us